PH12023552004A1 - Attenuated african swine fever virus and its use as a vaccine - Google Patents

Attenuated african swine fever virus and its use as a vaccine

Info

Publication number
PH12023552004A1
PH12023552004A1 PH1/2023/552004A PH12023552004A PH12023552004A1 PH 12023552004 A1 PH12023552004 A1 PH 12023552004A1 PH 12023552004 A PH12023552004 A PH 12023552004A PH 12023552004 A1 PH12023552004 A1 PH 12023552004A1
Authority
PH
Philippines
Prior art keywords
virus
attenuated
asf
present
swine fever
Prior art date
Application number
PH1/2023/552004A
Other languages
English (en)
Inventor
Yannick Blanchard
Le Potier Marie-Frã©Dã©Rique Blot
Olivier Bourry
Amã©Lie Chastagner
Evelyne Hutet
Dimna Mireille Le
Pierrick Lucas
Frã©Dã©Ric Paboeuf
Original Assignee
Agence Nat De Securite Sanitaire De Lalimentation De Lenvironnement Et Du Travail
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence Nat De Securite Sanitaire De Lalimentation De Lenvironnement Et Du Travail filed Critical Agence Nat De Securite Sanitaire De Lalimentation De Lenvironnement Et Du Travail
Publication of PH12023552004A1 publication Critical patent/PH12023552004A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH1/2023/552004A 2021-02-02 2022-01-31 Attenuated african swine fever virus and its use as a vaccine PH12023552004A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305138.6A EP4036226A1 (en) 2021-02-02 2021-02-02 Attenuated african swine fever virus and its use as a vaccine
PCT/EP2022/052183 WO2022167360A1 (en) 2021-02-02 2022-01-31 Attenuated african swine fever virus and its use as a vaccine

Publications (1)

Publication Number Publication Date
PH12023552004A1 true PH12023552004A1 (en) 2023-12-04

Family

ID=74661313

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/552004A PH12023552004A1 (en) 2021-02-02 2022-01-31 Attenuated african swine fever virus and its use as a vaccine

Country Status (10)

Country Link
US (1) US20240123048A1 (cg-RX-API-DMAC10.html)
EP (2) EP4036226A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024504878A (cg-RX-API-DMAC10.html)
KR (1) KR20230141819A (cg-RX-API-DMAC10.html)
CN (1) CN117295815A (cg-RX-API-DMAC10.html)
BR (1) BR112023015579A2 (cg-RX-API-DMAC10.html)
CA (1) CA3207287A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023008932A (cg-RX-API-DMAC10.html)
PH (1) PH12023552004A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022167360A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115851623A (zh) * 2022-12-27 2023-03-28 中国农业科学院兰州兽医研究所 非洲猪瘟mgf505-2r基因缺失减毒株的构建及作为疫苗的应用
CN118091160B (zh) * 2024-03-09 2025-06-06 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种非洲猪瘟病毒抗体的ipma检测方法与试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR682468A (fr) 1928-12-13 1930-05-28 Gas Fire Extinguisher Corp Du Extincteur d'incendie
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110093324B (zh) * 2019-04-26 2020-02-18 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 基因缺失的减毒非洲猪瘟病毒及其作为疫苗的应用

Also Published As

Publication number Publication date
JP2024504878A (ja) 2024-02-01
MX2023008932A (es) 2023-10-10
US20240123048A1 (en) 2024-04-18
WO2022167360A1 (en) 2022-08-11
BR112023015579A2 (pt) 2023-11-14
CN117295815A (zh) 2023-12-26
EP4036226A1 (en) 2022-08-03
CA3207287A1 (en) 2022-08-11
KR20230141819A (ko) 2023-10-10
EP4288526A1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
Quinn et al. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle
Früh et al. CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination
Snyder et al. Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells
Sanford et al. Deletion of the thymidine kinase gene induces complete attenuation of the Georgia isolate of African swine fever virus
US10537621B2 (en) Vaccine comprising beta-herpesvirus
Liu et al. Research progress on live attenuated vaccine against African swine fever virus
Slavuljica et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties
US20150165018A1 (en) Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
Neff et al. Characterization of western European field isolates and vaccine strains of avian infectious laryngotracheitis virus by restriction fragment length polymorphism and sequence analysis
MX2023008932A (es) Virus atenuado de la peste porcina africana y su uso como vacuna.
CN108064304A (zh) 可用于产生非典型cd8+ t细胞应答的方法和组合物
Lee et al. Growth kinetics and transmission potential of existing and emerging field strains of infectious laryngotracheitis virus
Wang et al. The first complete genome sequence and pathogenicity characterization of fowl adenovirus 11 from chickens with inclusion body hepatitis in Pakistan
CN104561092A (zh) 表达猪瘟病毒e2蛋白重组prrs病毒基因工程疫苗的构建方法和应用
CN106939320B (zh) 一种伪狂犬病毒js-2012株感染性克隆质粒、构建方法与应用
Liu et al. Construction of recombinant HVT expressing PmpD, and immunological evaluation against Chlamydia psittaci and Marek’s disease virus
Binjawadagi et al. Development of a porcine reproductive and respiratory syndrome virus-like-particle-based vaccine and evaluation of its immunogenicity in pigs
Moriyama et al. SARS-CoV-2 Omicron subvariants evolved to promote further escape from MHC-I recognition
Su et al. A recombinant field strain of Marek's disease (MD) virus with reticuloendotheliosis virus long terminal repeat insert lacking the meq gene as a vaccine against MD
JP7703030B2 (ja) 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
Cavadini et al. Molecular characterization of SG33 and Borghi vaccines used against myxomatosis
WO2022090131A1 (en) Recombinant african swine fever virus as live attenuated vaccine against african swine fever
Taus et al. Malignant catarrhal fever in American bison (Bison bison) experimentally infected with alcelaphine herpesvirus 2
JP2024504878A5 (cg-RX-API-DMAC10.html)
Tran et al. Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence